Cellectis (CLLS) Cash from Discontinued Operations (2022 - 2023)
Cellectis (CLLS) posted quarterly Cash from Discontinued Operations of 1000.0 for Q4 2023, up 100.03% year-over-year from 499.93 in Q4 2022, and up 200.0% quarter-over-quarter from 1000.0 in Q3 2023.
Powered by 
Analysis
Cellectis (CLLS) Cash from Discontinued Operations (2022 - 2023) Analysis & Trends
Cellectis' Cash from Discontinued Operations history runs 2 years deep, the most recent figure standing at 1000.0 for Q4 2023.
- In Q4 2023, Cash from Discontinued Operations rose 100.03% year-over-year to 1000.0; the TTM figure through Dec 2023 stood at 3644000.0 (up 80.41% YoY), while the FY2023 annual figure was 3644000.0, up 80.41% from the prior year.
- Cash from Discontinued Operations for Q4 2023 stood at 1000.0, up from 1000.0 in the prior quarter.
- The five-year high for Cash from Discontinued Operations was 1000.0 in Q4 2023, with the low at 8322000.0 in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 1,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Jun 30, 2023 | -1.67 Mn |
| Mar 31, 2023 | -1.97 Mn |
| Dec 31, 2022 | -3.47 Mn |
| Sep 30, 2022 | -3.16 Mn |
| Jun 30, 2022 | -5.53 Mn |
| Mar 31, 2022 | -6.44 Mn |